To further explore the robustness of treatment effects, we conducted subgroup analyses based on aHR derived from multivariable Cox proportional hazards models, with adjustment for other treatments, age, sex, stage, lymphatic metastasis, and serum biomarkers (CEA and NSE) as appropriate. This evidence concerns the gene ENO2 and Lymphatic Metastasis.